Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19.
G Moreira T, Gauthier CD, Murphy L, Lanser TB, Paul A, Matos KTF, Mangani D, Izzy S, Rezende RM, Healy BC, Baecher-Allan CM, Chitnis T, Kuchroo V, Weiner HL.
G Moreira T, et al. Among authors: weiner hl.
Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2220272120. doi: 10.1073/pnas.2220272120. Epub 2023 Mar 7.
Proc Natl Acad Sci U S A. 2023.
PMID: 36881624
Free PMC article.
Clinical Trial.